Modern Chinese Medicine Group Co., Ltd. (1643.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Modern Chinese Medicine Group Co., Ltd.
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
190
First IPO Date
January 15, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Hongli Zhang | Chief Executive Officer & Executive Director | 545,195 | 1965 |
| Yanru Jia | Joint Company Secretary & Executive Director | 296,327 | 1984 |
| Xinlei Sun | Executive Chairman | 544,038 | 1986 |
| Wen Tao Li | Chief Financial Officer | 0 | 1983 |
| Yuen Ting Tse | Joint Company Secretary | 0 | N/A |
Description
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.